(Total Views: 459)
Posted On: 04/30/2018 5:51:35 PM
Post# of 288
Highlights of QBL subsidiary on MMJ DEVELOPMENT.
• The board has an effective mix of both pharmaceutical and cannabis expertise working on MCL’s drug development strategy
• MCL’s strategy will position Canntab as a reliable and medical based ‘product of choice’
• Revenue is targeted in Australia in 2018 via Canntab sales under the Special Access Scheme
• MCL is targeting broader adoption in pain relief through the clinical trial process
See QBL-board and website;https://www.queenslandbauxite.com/
https://www.queenslandbauxite.com/
• The board has an effective mix of both pharmaceutical and cannabis expertise working on MCL’s drug development strategy
• MCL’s strategy will position Canntab as a reliable and medical based ‘product of choice’
• Revenue is targeted in Australia in 2018 via Canntab sales under the Special Access Scheme
• MCL is targeting broader adoption in pain relief through the clinical trial process
See QBL-board and website;https://www.queenslandbauxite.com/
https://www.queenslandbauxite.com/
(0)
(0)
Robert
Scroll down for more posts ▼
